GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » PB Ratio

Pharma Equity Group A/S (OCSE:PEG) PB Ratio : 4.97 (As of May. 09, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-09), Pharma Equity Group A/S's share price is kr0.189. Pharma Equity Group A/S's Book Value per Share for the quarter that ended in Dec. 2023 was kr0.04. Hence, Pharma Equity Group A/S's PB Ratio of today is 4.97.

The historical rank and industry rank for Pharma Equity Group A/S's PB Ratio or its related term are showing as below:

OCSE:PEG' s PB Ratio Range Over the Past 10 Years
Min: 1.48   Med: 1.48   Max: 6.55
Current: 5.16

During the past 13 years, Pharma Equity Group A/S's highest PB Ratio was 6.55. The lowest was 1.48. And the median was 1.48.

OCSE:PEG's PB Ratio is ranked worse than
77.02% of 1310 companies
in the Biotechnology industry
Industry Median: 2.505 vs OCSE:PEG: 5.16

During the past 12 months, Pharma Equity Group A/S's average Book Value Per Share Growth Rate was -96.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -67.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -49.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Pharma Equity Group A/S was -7.20% per year. The lowest was -67.20% per year. And the median was -22.70% per year.

Back to Basics: PB Ratio


Pharma Equity Group A/S PB Ratio Historical Data

The historical data trend for Pharma Equity Group A/S's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S PB Ratio Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.88 0.49 0.37 11.32

Pharma Equity Group A/S Quarterly Data
Mar16 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 9.08 10.45 8.20 11.32

Competitive Comparison of Pharma Equity Group A/S's PB Ratio

For the Biotechnology subindustry, Pharma Equity Group A/S's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's PB Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's PB Ratio falls into.



Pharma Equity Group A/S PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Pharma Equity Group A/S's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.189/0.038
=4.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Pharma Equity Group A/S  (OCSE:PEG) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Pharma Equity Group A/S PB Ratio Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.